Company intelligence / Profile preview
Argenica Therapeutics Limited
Nedlands, Western Australia, Australiaargenica.com.au ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
ARG-007 has proven safe and well tolerated in a Phase 1 clinical trial in healthy human volunteers. The company is currently conducting a Phase 2 clinical trial in acute ischaemic stroke patients across Australia, with all 92 patients now treated and entering the data lock phase with results expected in 2025.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Peptide therapeuticsNeuroprotective peptides
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
University of Western AustraliaPerron Institute for Neurological and Translational Science
Beyond the preview
Go deeper on Argenica Therapeutics Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Argenica Therapeutics Limited.